Orchid Pharma Reports QIP Proceeds Utilization and Project Timeline Revisions
Orchid Pharma Ltd · Others (Uncategorized) · 14 Nov 2026, 10:03 pm
Orchid Pharma Reports QIP Proceeds Utilization and Project Timeline Revisions Orchid Pharma Limited reported full utilization of its ₹400 crore QIP proceeds for the quarter ended 30th Sep'26 following shareholder-approved reallocation. Funds were reallocated from the postponed Alathur API expansion (cut to ₹0.36 crore) toward Orchid Bio-Pharma's Jammu facility (raised to ₹135 crore), debt prepayment (raised to ₹195.46 crore), and general corporate purposes (₹63.72 crore). Commercial operations at the greenfield Jammu manufacturing facility face significant delays due to ongoing land acquisition and farmer agreement procedures, with commercial startup now rescheduled to Feb'27.
Original exchange filing (PDF)
More announcements from Orchid Pharma Ltd
- Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company') · 18 Nov 2026
- Board Comments on fine levied by Stock Exchanges · 17 Nov 2026
- Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026 · 17 Nov 2026
- Declaration of Financial results for quarter and half year ended on September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Monitoring Agency Report for the Quarter-II ended on September 30, 2026 · 14 Nov 2026
- Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026 · 17 Nov 2026
